For the quarter ended December 2025, CareDx (CDNA) reported revenue of $108.39 million, up 25.2% over the same period last year. EPS came in at $0.12, compared to $0.18 in the year-ago quarter.
The reported revenue represents a surprise of +5.66% over the Zacks Consensus Estimate of $102.58 million. With the consensus EPS estimate being $0.24, the EPS surprise was -48.94%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how CareDx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Patient and digital solutions: $16.76 million versus $15.25 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +47.1% change.
- Revenue- Testing services: $78.37 million versus the two-analyst average estimate of $74.95 million. The reported number represents a year-over-year change of +22.8%.
- Revenue- Product: $13.26 million compared to the $12.45 million average estimate based on two analysts. The reported number represents a change of +16.6% year over year.
View all Key Company Metrics for CareDx here>>>
Shares of CareDx have returned -9.7% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CareDx, Inc. (CDNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
